Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood

Similar documents
Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?

HIV and Challenges of Vaccine Development

IMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START IN HIV INFECTED UGANDANS

IAS 2015 Towards an HIV Cure symposium Vancouver. Distinct HIV Genetic Populations in Effector Memory T Cells after Prolonged Therapy

Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir

Approaching a Cure Daniel R. Kuritzkes, MD

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

HIV Vaccines: Basic Science

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

Beyond the replication competent HIV reservoir: transcription and translation competent reservoirs

Why are validated immunogenicity assays important for HIV vaccine development?

Towards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco

Module R: Recording the HIV Reservoir

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Complete Transcriptome Analysis of Latently Infected CD4 + T Cells

CROI 2016 Review: Immunology and Vaccines

NIAID Vaccine Research Center: A Mission to Prevent HIV Infection

Supplementary Figure 1

What to Measure, How to Measure It

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

Questions and answers: HVTN 084 vaccine trial

Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers

Can HPV, cervical neoplasia or. HIV transmission?

T Memory Stem Cells: A Long-term Reservoir for HIV-1

How HIV Causes Disease Prof. Bruce D. Walker

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

What is the place of the monoclonal antibodies in the clinic?

Droplet Digital PCR, the new tool in HIV reservoir quantification? Ward De Spiegelaere

HIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA

The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial

Alexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout

Combinatorial Vaccines for AIDS and other Infectious Diseases

Single Cell Analysis of Lymph Node Tissue from HIV-1 Infected Patients Reveals that the Majority of CD4 + T- cells Contain One HIV-1 DNA Molecule

Section 6. Junaid Malek, M.D.

HIV cure: current status and implications for the future

Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir

HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies

Journal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers

Julianne Edwards. Retroviruses. Spring 2010

Section Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

Innovative diagnostics for HIV, HBV and HCV

Emerging Viruses. Part IIb Follow Up from Part I Vaccines and Inhibitors

Nature Medicine: doi: /nm.2109

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

HIV INFECTION: An Overview

Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION

Under the Radar Screen: How Bugs Trick Our Immune Defenses

Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses

Recombinant Protein Expression Retroviral system

The relation between HIV- 1 integration and latency

Working Group#1: Trial Endpoints, Biomarkers & Definitions

Low-Level Viremia in HIV

Supporting Information

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

2) What is the difference between a non-enveloped virion and an enveloped virion? (4 pts)

Supplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants

Spleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.

Universal Influenza Vaccine Development

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections

What do we measure when we measure cell associated HIV RNA

19 2 Viruses Slide 1 of 34

The Struggle with Infectious Disease. Lecture 6

Viruses 101., and concluded that living organisms do not crystallize. In other words,.

Massive infection and loss of memory CD4 + T cells in multiple tissues during acute SIV infection

Dr Anna Herasimtschuk

Potential Role of Human Endogenous Retrovirus K102 (HERV-K102) Particles in Resistance to HIV-1 Transmission

HIV Anti-HIV Neutralizing Antibodies

Bispecific Fusion Antibodies. Exhibit 100% Breadth and Picomolar Potency. Craig Pace, PhD

Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4

Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection

Reservoir BINGO. Methods Small group work/ large group discussion

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 T Cell Model without Inducing Global T Cell Activation

HIV recombination in the development of drug resistance

EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Professor Mark Bower Chelsea and Westminster Hospital, London

Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection

cure research HIV & AIDS

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

HIV 101: Fundamentals of HIV Infection

Modeling and Simulation of HIV-1 Intracellular Replication

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

From Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

Some living things are made of ONE cell, and are called. Other organisms are composed of many cells, and are called. (SEE PAGE 6)

MHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure

WHY? Viruses are considered non-living because they do:

Roger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018

DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED

HIV & AIDS: Overview

L I F E S C I E N C E S

October 26, Lecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell

Chapter 13B: Animal Viruses

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

Transcription:

Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood Richard A. Koup, MD June 29, 2013

Quantifying Intracellular HIV RNA Quantification of cell-associated HIV DNA is often used as a measure of past infection. Often used as a measure of the latent reservoir However, a large proportion of that DNA may be replication incompetent, and certainly transcriptionally inactive. Quantifying cell-associated HIV RNA could tell us: Which cells are transcriptionally active with respect to HIV Which cells are contributing to the plasma virus pool What is the viral burst size of HIV from a peripheral CD4 T cell How HIV antigens are expressed on the CD4 T cell surface in vivo What cellular processes are affected by active HIV transcription We therefore sought to quantify active HIV transcription in PBMC directly ex vivo

Which HIV RNA Should Be Measured?

9 Kb (genomic/gag) RNA without 2 Kb (Tat/Rev) RNA expression 9 Kb (genomic/gag) RNA and 2 Kb (Tat/Rev) RNA expression Viral protein expression and budding should be associated with CD4 down regulation

CD4 (+) Bright, Dim and Null Gating Strategy

Determining Active Expression of HIV RNA in CD4 T Cell Populations Sort CD4 Bright, Dim, and Null cells into multiple wells at varying numbers of cells per well Perform quantitative PCR for HIV Gag, Rev, and Tat RNA on each well Determine precursor frequency of cells actively expressing HIV Gag, Rev, and Tat RNA Use wells that are statistically likely to contain only a single HIV RNA expressing cell to determine the copy number of HIV RNA per cell in CD4 Bright, Dim, and Null cells + RNA PCR 9 Kb 2 Kb Gag Rev Tat

Determining Active Expression of HIV RNA CD4 Bright 3000 cells/well in CD4 T Cell Populations 1000 cells/well 300 cells/well Gag RNA 1:850 cells Rev RNA 1:3936 cells Tat RNA 1:4449 cells + RNA PCR 9 Kb 2 Kb Gag Rev Tat

Determining Active Expression of HIV RNA in CD4 T Cell Populations CD4 Bright CD4 Dim 3000 cells/well 30 cells/well 1000 cells/well 10 cells/well 300 cells/well Gag RNA 1:850 cells Rev RNA 1:3936 cells Tat RNA 1:4449 cells Gag RNA 1:64 cells Rev RNA 1:66 cells Tat RNA 1:80 cells + RNA PCR 9 Kb 2 Kb Gag Rev Tat

Determining Active Expression of HIV RNA in CD4 T Cell Populations CD4 Bright CD4 Dim 3000 cells/well 30 cells/well CD4 Null 500 cells/well 1000 cells/well 300 cells/well 10 cells/well Gag RNA 1:4746 cells Rev RNA 1:4746 cells Tat RNA 1:14749 cells Gag RNA 1:850 cells Rev RNA 1:3936 cells Tat RNA 1:4449 cells Gag RNA 1:64 cells Rev RNA 1:66 cells Tat RNA 1:80 cells + RNA PCR 9 Kb 2 Kb Gag Rev Tat

HIV Gag RNA copy number increases with decreasing CD4 surface expression Proportion of CD4 T cells Frequency of cells expressing 2kb RNA Copy No/2kB RNA + Cell 87% 1:2511 1.1% 1:58 11% 1:4746 VL = 47,259 CD4 = 244 Composite from 9 subjects

Activation Markers Further Identify Cells Expressing Spliced HIV RNA CD4 ICOS Rev RNA + = 1:34 CD8 CD38 Active HIV transcription is greatest in activated CD4 T cells

Question: Can we detect HIV-producing T cells using broadly neutralizing antibodies? Kwong, P.D, Mascola, J.R. 2012 Immunity 37(3):412-425

Broadly Neutralizing mab Staining of In Vitro BAL Infected CD4 T cells Mab concentration 3-5µg/ml

Can Broadly Neutralizing mabs Be Used to Sort In Vitro HIV-infected CD4 T Cells?

HIV RNA Copy Number Is Associated with CD4 Down-Regulation

Ex Vivo Index Sorting for HIV RNA PCR Index sorted 168 T cells into individual PCR wells (VL: >500,000, CD4: 24) 99 CD4 dim, 69 null CD56 - TCRγδ - Also stained with VRC07, PG9, CD27, CD45RO, ICOS and CD38 Fluorescence profile of each cell was stored Single-cell Sorting (e.g., CD4 dim vs null) CD4 CD27 PG9 CD45RO

Detecting HIV Transcription Ex Vivo Four wells were positive for HIV Tat, Rev, and Gag RNA One was positive for only Gag RNA All were CD4 dim (not null) HIV RNA + cells were PG9 dim and CD27 - Cells were variably positive for CD38 and ICOS

Conclusions Cell-associated viral replication in vivo can be quantified using cell sorting and Q-PCR for spliced and unspliced forms of HIV RNA Full HIV RNA transcription is associated with CD4 down-regulation in vivo The number of HIV RNA copies per cell increases with CD4 down-regulation HIV transcription is most frequent in T cells that express known activation markers The level of HIV env expression during active HIV replication in vivo is far less than it is on in vitro activated and infected T cells, making their detection by broadly neutralizing monoclonal antibodies difficult

Acknowledgements Immunology Laboratory Joseph Casazza David Ambrozak Alex Vostal Human Immunology Section Daniel Douek Brenna Hill Eli Boritz Special thanks to: Frank Maldarelli John Mellors John Coffin